GlobeNewswire 10/02/2022 Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Synd...
GlobeNewswire 01/02/2022 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...
GlobeNewswire 23/01/2022 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeut...
GlobeNewswire 13/01/2022 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeu...
GlobeNewswire 13/01/2022 Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
GlobeNewswire 10/01/2022 Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodege...
GlobeNewswire 17/11/2021 Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commerc...
GlobeNewswire 04/11/2021 Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
GlobeNewswire 06/10/2021 Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Prog...
GlobeNewswire 29/09/2021 Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor S...
GlobeNewswire 27/09/2021 Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
GlobeNewswire 21/09/2021 Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multi...
GlobeNewswire 09/09/2021 Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
GlobeNewswire 07/09/2021 CENTOGENE Reports Second Quarter 2021 Financial Results
GlobeNewswire 26/08/2021 Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
GlobeNewswire 04/08/2021 Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
GlobeNewswire 03/08/2021 Zymergen Provides Business Update
GlobeNewswire 02/08/2021 Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to i...
GlobeNewswire 25/07/2021 Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Pa...
GlobeNewswire 15/07/2021 Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potenti...
GlobeNewswire 28/06/2021 Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL75...
GlobeNewswire 17/05/2021 F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
GlobeNewswire 10/05/2021 CENTOGENE Extends Global Parkinson’s Disease Study
GlobeNewswire 03/05/2021 Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
GlobeNewswire 01/05/2021 Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibit...